Meeting Banner
Abstract #1739

The value of hepatocyte fraction based on pharmacokinetic model using gadoxetate disodium in assessment of liver fibrosis stage

En-Ming Cui1, Wan-Sheng Long1, Fan Lin2, Qing Li3, Jun-Hua Wu4, Zhuo-Yong Li1, Yong Lan1, and Ying-Jie Mei5

1Radiology, Jiangmen Central Hospital, Affiliated Jiangmen Hospital of Sun YAT-SEN University, Jiangmen, China, 2Radioogy, The First Affiliated Hospital of Shenzhen University, Health Science Center, Shenzhen Second People's Hospital, Shenzhen, China, 3Pathology, Jiangmen Central Hospital, Affiliated Jiangmen Hospital of Sun YAT-SEN University, Jiangmen, China, 4Hepatobiliary Surgery, Jiangmen Central Hospital, Affiliated Jiangmen Hospital of Sun YAT-SEN University, Jiangmen, China, 5Healthcare, Philips, Guangzhou, China

Liver fibrosis is prevalent in patients with chronic liver disease, and the early diagnosis of liver fibrosis is still challenging in clinical practice. In this study, the hepatocyte fraction (HepF) was calculated using the T1 value before and 20min after Gd-EOB-DTPA injection (hepatobiliary phase). Patients with severe liver fibrosis showed significantly higher T1 value and lower HepF value. In addition, HepF achieved the best performance in differentiation of liver fibrosis from non-fibrosis (AUC = 0.74), and mild liver fibrosis from severe liver fibrosis (AUC = 0.95), proving HepF can be a better noninvasive quantitative method for liver fibrosis evaluation.

This abstract and the presentation materials are available to members only; a login is required.

Join Here